Is Savaysa already dead?

Discussion in 'Daiichi-Sankyo' started by Anonymous, Apr 23, 2015 at 12:00 AM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Well, since Savaysa is never going to get good MM coverage, I guess it is already dead. And nevermind that massive black box warning about killing more patients with normal renal function that warf.
     

  2. Anonymous

    Anonymous Guest

    To answer your original question.......Yes, Savaysa is dead. God save the Queen
     
  3. Anonymous

    Anonymous Guest

    Heads should roll
     
  4. Anonymous

    Anonymous Guest

    Black box warning aside and the managed care coverage...it will be #1 over all the others
     
  5. Anonymous

    Anonymous Guest

    This topic is
     
  6. Anonymous

    Anonymous Guest

    How is Savaysa doing? Left the company in March. Just curious
     
  7. Anonymous

    Anonymous Guest

    Anyone thinking it could compete is an idiot
     
  8. Anonymous

    Anonymous Guest

    Management all idiots
     
  9. Anonymous

    Anonymous Guest

    You are delusional. It's dead.
     
  10. Anonymous

    Anonymous Guest

    Who is the incompetent one for this?
     
  11. Anonymous

    Anonymous Guest

    Seriously is it really that bad?! I have no idea...left in March.
     
  12. Anonymous

    Anonymous Guest

    Yes
     
  13. Anonymous

    Anonymous Guest

    Murdered by Glenn Gormley LMAO
     
  14. Anonymous

    Anonymous Guest

    And how is our great new POA message going to stop this? Keep drinking the cool aid kiddies1


    Bayer, J&J touting Xarelto trial data to counteract Eliquis surge


    June 30, 2015 | By Carly Helfand


    For a while now, Bayer and Johnson & Johnson's ($JNJ) Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.



    As Bayer's management acknowledged last week, "the impression that Eliquis is a better drug exists in the marketplace," Bernstein analyst Ronny Gal wrote in a note to investors. But the way the German pharma's leaders see it, it's "wrong."

    Xarelto trials were done in the most severe patients, Bayer told Gal, which helped Eliquis--a collaboration between Pfizer ($PFE) and Bristol-Myers Squibb ($BMY)--come out looking stronger. And to combat the idea that Eliquis works better, Bayer this month kicked off a campaign to educate the market on the trial data differences.

    Not too long ago, Bayer and J&J didn't have much to worry about when it came to Eliquis. Despite its rosy trial data, the Pfizer/BMS therapy got off to a sluggish start, well underperforming analysts' early launch expectations.

    Now, though, things have turned around for the third-to-market med, with DTC ads and beefed-up sales efforts helping its top-line haul grow to $774 million last year--a far cry from the $146 million it posted the year prior.

    And there's new competition in Daiichi Sankyo's Savaysa, too. While that treatment's black box safety warning renders it "not a realistic alternative" to Xarelto, Daiichi could get aggressive with pricing, meaning Xarelto "will have to give some rebates in the U.S.," Gal noted.

    Still, Bayer and J&J need not worry too much. "Pricing and access should still continue to be strong," Gal wrote, and the pair's extensive clinical trial program is working to make sure Xarelto keeps the lead in label indications. And both of those will help the drug maintain a hefty piece of the market-share pie, he predicted

    After the management meeting, "we came away less concerned for Xarelto," he wrote. "But it would be nice upside if the competitive message gains traction."
     
  15. Anonymous

    Anonymous Guest

    What does Gormley do all day?
     
  16. Anonymous

    Anonymous Guest

     
  17. Anonymous

    Anonymous Guest

    I'm jealous. Just kidding...that's a typical work day for me too. Gay clown wheelchair porn...pays the bills and I'm happy:)
     
  18. Anonymous

    Anonymous Guest

    Heck... and all this time I thought I was the only one!
     
  19. Anonymous

    Anonymous Guest

    CEOs get fired too... ask the Donald.
     
  20. Anonymous

    Anonymous Guest

    What does Gormley do all day?

    Don't know. But, he requires lots of Vaseline and tissues.[/QUOTE]


    GG here: I don't require tissues.